PriceTargets.com logo

Fennec Pharmaceuticals - FRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
C$9.69 As of 09/27/2023 01:00 AM ET
▼ -0.4 (-3.96%)

This chart shows the closing price for FRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fennec Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FRX

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Fennec Pharmaceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$9.69.

This chart shows the closing price for FRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Fennec Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/22/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight
10/20/2022HC WainwrightReiterated RatingBuy
9/7/2022Capital One FinancialReiterated RatingOverweight
5/12/2022WedbushReiterated RatingOutperform
3/24/2022Maxim GroupReiterated RatingBuyC$10.00
11/30/2021Maxim GroupInitiated CoverageBuyC$10.00
11/30/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral
6/3/2021HC WainwrightReiterated RatingBuy
3/17/2021WedbushReiterated RatingOutperform
6/5/2020Cantor FitzgeraldReiterated RatingOverweight
10/10/2018Dawson JamesReiterated RatingBuy
(Data available from 9/28/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/1/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Read More

Today's Range

Now: C$9.69
Low: C$9.69
High: C$9.69

50 Day Range

MA: C$10.76
Low: C$9.59
High: C$11.27

52 Week Range

Now: C$9.69
Low: C$9.59
High: C$14.41

Volume

1,000 shs

Average Volume

682 shs

Market Capitalization

C$257.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Fennec Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Fennec Pharmaceuticals in the last twelve months: Cantor Fitzgerald, and HC Wainwright.
View the latest analyst ratings for FRX.

What is the current price target for Fennec Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Fennec Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Fennec Pharmaceuticals in the next year.
View the latest price targets for FRX.

What is the current consensus analyst rating for Fennec Pharmaceuticals?

Fennec Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FRX will outperform the market and that investors should add to their positions of Fennec Pharmaceuticals.
View the latest ratings for FRX.

What other companies compete with Fennec Pharmaceuticals?

Other companies that are similar to Fennec Pharmaceuticals include VIVO Cannabis, Emblem, Sernova, Oncolytics Biotech and ProMetic Life Sciences. Learn More about companies similar to Fennec Pharmaceuticals.

How do I contact Fennec Pharmaceuticals' investor relations team?

Fennec Pharmaceuticals' physical mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company's listed phone number is +1-919-6364530. The official website for Fennec Pharmaceuticals is fennecpharma.com. Learn More about contacing Fennec Pharmaceuticals investor relations.